DEMENTIA: A REVIEW
DOI:
https://doi.org/10.53555/nnas.v8i2.1365Keywords:
Dementia, Clinical Care, Cognitive Impairment, Alzheimer’s DiseaseAbstract
Dementia is any decline in cognition that is significant enough to interfere with independent, daily functioning. The aim of this review is to summarize the current findings in the field and address the important contributions of cerebrovascular, physiologic, and cellular alterations to cognitive impairment in these human dementias. Dementia is best characterized as a syndrome rather than as one particular disease. The causes of dementia constitute two broad categories of disease: those that are“neurodegenerative”(originally called "irreversible")and non-neurodegenerative (potentially "reversible"). Lastly. The treatment modalities of these dementias and their management is discussed.
References
R.A. Sperling et al. Toward defining the preclinical stages of alzheimer's disease: recommendations from the national institute on aging-alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011).
W.D. Brenowitz et al. Alzheimer's disease neuropathologic change, lewy body disease, and vascular brain injury in clinic- and community-based samples. Neurobiol Aging (2017).
W.D. Brenowitz et al. Cerebral amyloid angiopathy and its co-occurrence with alzheimer's disease and other cerebrovascular neuropathologic changes. Neurobiol Aging (2015).
J.T. O'Brien et al. Vascular cognitive impairment. Lancet Neurol (2003)
Gale SA, Acar D, Daffner KR. Dementia. Am J Med 2018; 131:1161–9.
Raz L, Knoefel J, Bhaskar K. The neuropathology and cerebrovascular mechanisms of dementia. J Cereb Blood Flow Metab 2016; 36:172–86. doi:10.1038/jcbfm.2015.16
Petrovitch H, Ross GW, Steinhorn SC, Abbott RD, Markesbery W, Davis D, et al. AD lesions and infarcts in demented and non-demented Japanese-American men. Ann Neurol 2005; 57: 98–103.
Schreiber S, Bueche CZ, Garz C, Braun H. Blood brain barrier breakdown as the starting point of cerebral small vessel disease?— New insights from a rat model. Exp Transl Stroke Med 2013; 5: 4.
Farkas E, De Jong GI, de Vos RA, Jansen Steur EN, Luiten PG. Pathological features of cerebral cortical capillaries are doubled in Alzheimer's disease and Parkinson's disease. Acta Neuropathol 2000; 100: 395–402.
Yang Y, Rosenberg GA. Blood-brain barrier breakdown in acute and chronic cerebrovascular disease. Stroke 2011; 42: 3323–3328.
Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/american Stroke Association. Stroke 2011; 42: 2672–2713.
Tisher A, Salardini A. A Comprehensive Update on Treatment of Dementia. Semin Neurol 2019; 39:167–78. doi:10.1055/s-0039-1683408
Prince M, Guerchet M, Prina M. Policy Brief for Heads of Government: The global Impact of Dementia 2013–2050 . London: Alzheimer's Disease International; 2013
Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM. Monetary costs of dementia in the United States . N Engl J Med 2013; 368(14) 1326-133
Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care . Lancet 2017; 390 (10113): 2673-2734
Richard E, Van den Heuvel E, Moll van Charante EP. , et al. Prevention of dementia by intensive vascular care (PreDIVA): a cluster-randomized trial in progress . Alzheimer Dis Assoc Disord 2009; 23 (03) 198-204
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Journal of Advance Research in Applied Science

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.